LABA Label Changes Could Reinvigorate Single-Ingredient Products
FDA's new labeling and use guidelines for long-acting beta agonists may present some sales challenges, but also may create a new market for older drugs
FDA's new labeling and use guidelines for long-acting beta agonists may present some sales challenges, but also may create a new market for older drugs